ReviewViruses2026
Targeting cccDNA for Degradation: Endogenous- and Exogenous-Based Methods of Nuclear-Localized DNA Destruction in the Context of Chronic Hepatitis B Infection.
Review in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability to facilitate cellular degradation or achieve therapeutic destruction of targeted noxious DNA is recognized as a major goal for the treatment of various viral infections. In the case of chronic hepatitis B, targeted DNA degradation of the episomal viral genome found in the nucleus of infected hepatocytes is key to achieving a true cure. However, mechanisms of targeted DNA degradation without excessive broadscale cytotoxicity are still under investigation by researchers. This review summarizes several current systems known to have the ability to target nuclear-localized DNA, including endogenous methods of DNA degradation that may be harnessed therapeutically and exogenous methods such as CRISPR or other xenobiotics, with a focus on their potential application in hepatitis B treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.